CLAIMS

1. Use of a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one influenza antigen in the manufacture of a medicament for stimulating an immune response to an influenza antigen in a human who is at least 65 years old, wherein the fusion protein is to be administered in a dose that generates an immune response to the influenza antigen ~~and at least one adverse systemic reaction~~ by the human who is at least 65 years old that provides protective immunity against an infection consequent to exposure of the human to a source of the influenza antigen ~~related to the flagellin component of the fusion protein is less severe than the dose would generate in a human less than 65 years old.~~

~~2. The use of claim 1, wherein the immune response in the human provides protective immunity against an infection consequent to exposure of the human to a source of the influenza antigen.~~

23. The use of claim 1, wherein the dose is at least one dose selected from the group consisting of a 0.5 µg dose, 1 µg dose, 2 µg dose, 3 µg dose, 4 µg dose, 5 µg dose, 6 µg dose, 7 µg dose, 8µg dose, 10µg dose, 15µg dose, 20 µg dose, 25µg dose and a 30µg dose.

34. The use of claim 23, wherein the dose is at least one dose selected from the group consisting of a 0.5 µg dose, 1 µg dose, 2 µg dose, 3 µg dose, 4 µg dose, 5 µg dose, 6 g dose, 7 µg dose, and 8µg dose.

45. The use of claim 23, wherein the dose is at least one dose selected from the group consisting of a 5 µg dose, 6 µg dose, 7 µg dose, 8µg dose, 10µg dose, 15µg dose, 20µg dose, 25µg dose and a 30µg dose.

56. The use of claim 1, wherein the dose is at least one dose selected from the group consisting of an 8µg dose, 10µg dose, 15µg dose, 20µg dose, 25 µg dose and a 30µg dose.

67. The use of claim 1, wherein the influenza antigen is a hemagglutinin influenza antigen.

78. The use of claim 1, wherein the influenza antigen is an influenza A antigen.

89. The use of claim 1, wherein the influenza antigen is an influenza B antigen.

940. The use of claim 1, wherein the influenza antigen is an influenza C antigen.

1044. The use of claim 1, wherein the fusion protein is to be administered intramuscularly to the human.

1142. The use of claim 1, wherein at least one subsequent dose of the fusion protein is to be administered to the human.

1243. The use of claim 1, wherein the fusion protein includes SEQ ID No. 1.

1344. Use of claim 1, wherein the influenza antigen of the fusion protein is associated with a particle in the

manufacture of the medicament for stimulating the immune response in the human.

1415. The use of claim 1314, wherein the particle is a virosome, liposome, biodegradable microsphere, self-assembling peptide nanoparticle, virus-like particle or combinations thereof.

1516. The use of claim 1415, wherein the particle is a self-assembling peptide nanoparticle.

1617. The use of claim 1415, wherein the particle is a virosome.

1718. The use of claim 1, wherein the fusion protein is at least one dose selected from the group consisting of a 8µg dose, 10 µg dose, 15µg dose, 20 µg dose, 25 µg dose and a 30µg dose.

~~19. The nucleic acid sequence as set forth in Seq ID 2.~~

~~20. The nucleic acid sequence as set forth in Seq. ID 4.~~

18~~21~~. The ~~nucleic acid~~ use of claim 1, wherein the fusion protein is the polypeptide sequence as set forth in Seq ID 6.

19~~22~~. The use of claim 1, wherein the fusion protein is the polypeptide sequence as set forth in Seq ID 3.

~~23. The polypeptide sequence as set forth in Seq ID 5.~~

20~~24~~. The use of claim 1, wherein the fusion protein is the polypeptide sequence as set forth in Seq ID ~~87~~.

21~~25~~. The use of claim 1, wherein the dose administered to the human who is at least 65 years old is about a 3 µg to about a 50 µg dose, about a 4 µg to about a 50 µg dose or about a 5 µg to about a 50 µg dose.